Adaptive Biotechnologies Corporation will release its financial results for the second quarter of 2026 after the market closes on July 29, 2026. The announcement will provide insights into the performance of its commercial-stage biotechnology operations, which focus on translating the genetics of the adaptive immune system into clinical products. A conference call to discuss the results is scheduled for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on the same day.

The webcast will be accessible live through the "Investors" section of the company website at www.adaptivebiotech.com . An archived version of the call will be available for replay within 24 hours of the event, allowing stakeholders to access the information at their convenience.

Key Event Details

Adaptive Biotechnologies operates through two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The company leverages its proprietary immune medicine platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics for diseases such as cancer and autoimmune disorders.

Morgan Stanley analyst Tejas Savant has maintained an Equal-Weight rating on Adaptive Biotechnologies (NASDAQ: ADPT) while raising the stock's price target to $20 from the previous $18. The adjustment reflects a revised valuation outlook for the biotechnology firm. The rating remains unchanged, indicating a neutral stance on the stock's performance relative to the broader market. The new price target suggests a specific upside potential based on the firm's current analysis.

Rating and Price Target Details

The decision to adjust the price target while keeping the rating steady highlights a balanced view of the company's prospects. The following table summarizes the analyst's revised stance:

The Equal-Weight rating implies that the stock is expected to perform in line with the sector or the analyst's coverage universe over the specified period. The increase in the price target indicates an acknowledgment of improved fundamentals or market conditions affecting the company's valuation.